@mdwrtcom profile picture
CLINICAL TRIAL OF THE DAY @mdwrtcom
Joined April 2022
  • Tweets 936
  • Following 71
  • Followers 278
Photos and videos
Progression-free survival differed significantly among arbitrarily defined endocrine sensitivity groups in metastatic #breastcancer #SABCS23
Stephanie Graff, MD, FACP, FASCO@DrSGraff
5 Dec 2023
Dr. Barrios highlights how very different hormone receptor positive metastatic breast cancer can be—and compares to the Aurora trial’s validation of those definitions #SABCS23 @OncoAlert
1
380
In hemodynamically unstable brain-dead potential heart donors, intravenous levothyroxine infusion did not result in significantly more hearts being transplanted than saline infusion bit.ly/4ajRofW #DataViz #visualabstract
1
229
DeLLphi-301 trial: #tarlatamab showed antitumor activity with durable objective responses and promising survival outcomes in patients with previously treated small-cell #lungcancer bit.ly/3RDR98e #DataViz #visualabstract
1
211
#FLAURA2 trial: first-line treatment with #osimertinib-#chemotherapy led to a significantly longer PFS than osimertinib monotherapy among patients with #EGFR-mutated advanced #NSCLC bit.ly/3GoNuop #visualabstract #DataViz #cancertwi @dplanchard
4
3
724
#GRADUATE clinical trials: #gantenerumab led to a lower amyloid plaque burden than placebo in #AlzheimersDisease but was not associated with slower clinical decline bit.ly/3uxobxN #visualabstract #DataViz #Alzheimers @Roche
1
172
#ARTESIA trial: in patients with subclinical #atrialfibrillation, #apixaban resulted in a lower risk of #stroke or #systemicembolism than aspirin but a higher risk of major bleeding bit.ly/40MMm7l #visualabstract #dataviz #AF
3
244
#CheckMate 901 trial: #nivolumab plus gemcitabine–cisplatin resulted in significantly better outcomes in patients with previously untreated advanced #urothelialcarcinoma than gemcitabine–cisplatin alone bit.ly/3uao9eV #DataViz #visualabstract
3
376
Spasertan failed to improve focal segmental glomerulosclerosis outcomes compared to irbesartan bit.ly/478b5Ft #VisualAbstract #nephrology #kidney #KidneyTwitter
2
1
231
ENVISION trial: in patients with IgA #nephropathy, 12 months of treatment with #sibeprenlimab resulted in a significantly greater decrease in proteinuria than placebo bit.ly/46b8Xvo #dataviz #visualabstract @Visterra_Inc #ASN2023 #ASN #kidneyweek @IgAN_JBarratt
2
3
506
Final overall survival analysis from KEYNOTE-826 shows sustainable benefit with first-line #pembrolizumab in persistent, recurrent, or metastatic cervical #cancer bit.ly/3Sq4QbO #VisualAbstract #oncology
2
253
Treatment with #thalidomide resulted in a reduction in bleeding in patients with recurrent bleeding due to small-intestinal #angiodysplasia bit.ly/3FJw85b #visualabstract #dataviz
1
133
After release of EMBARK trial results the question if failure to fulfill primary endpoint will jeopardize Elevidys™ full approval for Duchenne muscular dystrophy stands bit.ly/46TY0PY
1
1
233
AiDAPT ISRCTN Registry: hybrid closed-loop therapy significantly improved maternal #glycemiccontrol during #pregnancy complicated by type 1 #diabetes bit.ly/3QRFQZX #dataviz #visualabstract
1
133
EV-302/KEYNOTE-A39: #enfortumab vedotin #pembrolizumab improved overall survival by 53% compared to platinum-based chemotherapy in urothelial #cancer
Tom Powles
@tompowles1
22 Oct 2023
Enfortumab vedotin & Pembrolizumab improving PFS & OS by 55% & 53% respectively compared to platinum based chemo in 1st line UC ( avelumab in 30%). Chemo has not been beaten before (despite multiple efforts). RR and CR of 68% & 29% is hard to beat. DOR not reached (1/3)#ESMO2023
1
1
563
AEGEAN trial: in resectable #NSCLC, perioperative #durvalumab was associated with significantly greater event-free survival and pathological complete response than neoadjuvant chemotherapy alone bit.ly/46Tyqus #visualabstract #dataviz #cancertwi #lungcancer @FouadMD
6
16
1,487
Radulotatug deruxtecan demonstrated impressive response rates in heavily pretreated platinum-resistant #OvarianCancer patients #VisualAbstract #oncology #cancer #ESMO2023
1
1
170
Second interim analysis from LITESPARK-005 Trial demonstrated significant improvement in primary endpoint of progression free survival accompanied by better QoL compared to everolimus treatment in pretreated renal #cancer #VisualAbstract #oncology #ESMO2023
2
190
New data from NATALEE trial indicate sustained invasive disease-free survival for adjuvant ribociclib in all major subgroups of early #breastcancer patients bit.ly/45GmNWr #VisualAbstract #oncology #ESMO23
1
2
324
Two short courses of teplizumab allowed to diminish progression of newly diagnosed type 1 #diabetes , yet failed to improve glycemic control bit.ly/46ZXfEZ #VisualAbstract #endocrinology
92
ATLANTIS trial: titrated low-dose #amitriptyline was superior to placebo as a second-line treatment for #IBS across multiple outcomes, and was safe and well tolerated bit.ly/3tByP66 #visualabstract #dataviz #gastrotwi #Gastroenterology @amanda_horler
1
11
25
2,871
Load more